ETON Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Eton Pharmaceuticals (NASDAQ: ETON)
›
Eton Pharmaceuticals (NASDAQ: ETON) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 61.15 USD on 20 November 2026, up 220.6% over 52 weeks. Its 52-week range is 14.27 USD to 70.64 USD: the price is 13.4% below the high and 328.6% above the low.
At a market capitalisation of 1.77B USD, it trades at 39.8 times trailing earnings and 18.6 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 63% for ETON.
Eton Pharmaceuticals reports return on equity of -17.6%, an operating margin of 31.3% and revenue up 157.9% year over year.
It holds more cash than debt, a net cash position of 31.29M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 80.75 USD is 32.0% above the current price. The next earnings report is expected on 25 March 2027.